Biocrede

Biocrede

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Biocrede Inc. is a private, services-oriented company founded in 2019 and headquartered in San Francisco, California. It functions as a hybrid advisory and investment firm, targeting early-stage biomedical and digital health companies with services designed to accelerate their path to market and secure funding. The company's model leverages a stated 15-year team track record to offer strategic planning, grant writing, M&A support, and startup operational solutions, positioning itself as a catalyst for small business growth in the biotech sector.

Digital HealthAI / Machine Learning

Technology Platform

A services and advisory platform leveraging AI/ML and specialized expertise in grant writing, IP strategy, ethnographic research, and M&A to accelerate biotech and digital health startups.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing number of biotech and digital health startups creates a large addressable market for specialized advisory services.
Increased competition for non-dilutive government grants (e.g., SBIR) drives demand for expert grant writing support.
A robust biopharma M&A environment generates need for valuation and due diligence services for small companies.

Risk Factors

Revenue is highly dependent on the funding climate for early-stage biotech, which is cyclical.
Lack of publicly disclosed leadership, client portfolio, and detailed track record poses a significant credibility challenge.
The dual role as advisor and potential investor in clients could create conflicts of interest.

Competitive Landscape

Biocrede competes with a wide range of entities including specialized life science consulting firms, boutique investment banks, freelance grant writers, and the internal business development teams of venture capital firms. Its differentiation is purportedly a full-service, hands-on approach tailored specifically to very small biomedical businesses, a segment sometimes overlooked by larger players.